Cancer Immunology Project Awards

About this scheme

Key information

Career level
Established independent researcher
Clinician
Non-clinical researcher
Research area
Immunology
Cancer biology
Full application
Committee review
Funding period
Up to 3 years
Funding amount
Up to £300k
Cancer Immunology Project Awards catalyse research and build the UK's research base in cancer immunology by funding immunologists from non-cancer fields.

Applications are accepted from:

  • Scientists, clinicians or health care workers from UK universities, medical schools, hospitals and some research institutes.
  • The lead applicant (PI) must be an immunologist who should not have a demonstrated track record in cancer research.
  • Collaborations with cancer researchers/clinicians are strongly encouraged to deliver the project but are not a mandatory requirement.

If you have a demonstrated track record in cancer, or are a group leader at a CRUK core-funded Institute, you are not eligible to apply for this award as the lead PI, but may act as a co-investigator or collaborator.

The aim of the scheme is to build capacity in cancer immunology; therefore, if you already have a demonstrated track record in cancer research, our other opportunities in discovery research may be more suitable for your research.

Scientific remit

Your proposal should address key questions in the immunology of cancer. Applications can be in any area of immunological research, providing the cancer relevance is clearly articulated in the proposal, including any of the following key areas:

  • Cellular and molecular immunology: including but not limited to mechanisms of tolerance, the regulation of immune function, the development of memory, the interaction of immune cells with tissues and enhancing the immune system’s ability to detect and destroy cancer.

  • Inflammation, allergy, transplantation and autoimmunity: how the basic understanding of relevant mechanisms involved could drive forward our understanding of cancer as well as how sensing of endogenous changes in immune homeostasis, such as tissue damage, impacts on the sensing and development of cancers.

  • Immune response to infection: including but not limited to immunity and disease susceptibility/resistance and the development of adverse infections in response to immune therapy or biological drug intervention.

If you are looking for support for the discovery and development of new biotherapeutics or immunomodulatory agents, explore our opportunities in drug discovery and development.

You can apply for funding of up to £300k, which can be used for:

  • Salaries for researchers and technical staff
  • Running expenses
  • Equipment
 

How to apply to this scheme

​Application process

  1. You must email us with a one-page summary of your proposal, a list of potential collaborators and your CV. We advise you do this at least one month before the deadline.
  2. If your proposal is eligible, we will invite you to make a formal application through our electronic Grants Management System (Flexi-Grant)
  3. Your application will be assessed by an Expert Review Panel.
  4. The final funding decision will be made by our Discovery Research Committee.

 

Timelines

Applications for Cancer Immunology Project Awards are considered twice a year.

Deadline

Committee review

 

 

15 July 2021

November 2021

 

 

27 January 2022

June 2022

 

 

Before you begin your application

Please read:

The Discovery Research Committee will judge your proposal based on:

  • Scientific excellence: all applications must have a strong scientific rationale, as well as appropriate experimental design and statistical analyses, to support the proposed research proposal. 
  • Cancer relevance: value of the proposed work in advancing the fundamental understanding of cancer or improving how cancer is diagnosed and/or treated.
  • Track record: the lead applicant and/or team members should have an excellent track record and potential to produce outstanding results.
  •  Excellent team and collaborative environment: suitability and feasibility of the Lead Applicant(s) (and supporting roles) to carry out the proposed research with access to the resources and facilities required for the successful fulfilment of the Award. The added value of the proposed collaboration and the individual contributions, as well as the steps taken to ensure an effective collaboration.
  • Resources requested: the costs requested in an application should be for the direct costs of the research and be reasonably justified in line with the experimental plans, leveraging existing resources where appropriate. 

The Committee will also consider how your proposed research aligns with our strategic priorities, as set out in our Discovery Research Statement of Intent and our broader Research Strategy.

Applications are assessed by the Cancer Immunology Expert Review Panel. Final funding decisions are made by the Discovery Research Committee.

Cancer Research UK contact details

​When this funding scheme reopens, please contact the research funding manager for this scheme to discuss your proposal before starting your application.

James Pegge PhD - Research Grants Manager

james.pegge@cancer.org.uk

Tel: 020 3469 6147

More opportunities for discovery researchers

Discovery Research

We support a broad portfolio of discovery research, including basic biology, genetics and immunology, biomarker discovery and preclinical studies, and engineering and physical sciences applied to cancer. We have a variety of grant funding and other opportunities to accelerate your research.

Case studies

Creating a genomic map of the immune response

Creating a genomic map of the immune response

Sarah Teichmann and Jacqui Shields have teamed up to create a genomic map of the immune response to cancer, making the most of their complementary skills in immunology and cancer research.

Discovering underlying immunological questions in cancer

White and Red Blood Cells - image courtesy of the EM Unit

Andrew Mellor is using funding from our Immunology Project Award to explore the link between dying cells and inflammatory responses that promote cancer development.